Supernus Pharmaceuticals Shares Outstanding 2011-2018 | SUPN

Current and historical number of shares outstanding for Supernus Pharmaceuticals (SUPN) from 2011 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Supernus Pharmaceuticals Annual Shares Outstanding
(Millions of US $)
2017 $53
2016 $52
2015 $51
2014 $42
2013 $32
2012 $17
2011 $2
2010 $2
Supernus Pharmaceuticals Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $54
Q1 2018 $54
Q4 2017 $53
Q3 2017 $54
Q2 2017 $53
Q1 2017 $53
Q4 2016 $52
Q3 2016 $52
Q2 2016 $52
Q1 2016 $51
Q4 2015 $51
Q3 2015 $52
Q2 2015 $52
Q1 2015 $45
Q4 2014 $42
Q3 2014 $43
Q2 2014 $42
Q1 2014 $41
Q4 2013 $32
Q3 2013 $31
Q2 2013 $31
Q1 2013 $31
Q4 2012 $17
Q3 2012 $24
Q2 2012 $17
Q1 2012 $2
Q4 2011 $2
Q3 2011 $2
Q2 2011 $2
Q1 2011 $2
Q4 2010 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.410B $0.302B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.458B 10.72
Teva Pharmaceutical Industries (TEVA) Israel $22.859B 6.39
Mylan (MYL) United Kingdom $19.184B 8.16
Bausch Health Cos (BHC) Canada $7.619B 5.69
Dr Reddy's Laboratories (RDY) India $5.346B 23.88
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.588B 4.40
Akorn (AKRX) United States $2.332B 11.55
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.801B 115.47
CymaBay Therapeutics (CBAY) United States $0.714B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.628B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Voyager Therapeutics (VYGR) United States $0.589B 0.00
Homology Medicines (FIXX) United States $0.582B 0.00
Corium (CORI) United States $0.314B 0.00
Teligent (TLGT) United States $0.220B 0.00
Sol-Gel Technologies (SLGL) Israel $0.124B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.115B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.073B 0.00
Versartis (VSAR) United States $0.063B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.043B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.023B 0.00
Acasti Pharma (ACST) Canada $0.019B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00